Key result
Nighttime RMS40 < 6.1 μV in the third intercostal space lead V2 detected by a novel Holter-SAECG significantly predicted VT/VF recurrence in patients with Brugada syndrome (HR 6.14).
Why the study?
Does the measurement of site-specific late potentials using a novel Holter-SAECG system predict cardiac events in patients with Brugada syndrome?
Observational (n=41)
No
Does the measurement of site-specific late potentials using a novel Holter-SAECG system predict cardiac events in patients with Brugada syndrome?
Site-specific late potentials in the 3rd intercostal space V2 lead measured by a novel Holter-SAECG system can serve as a useful marker for risk stratification in patients with Brugada syndrome.
Site-specific late potentials on novel Holter-SAECG may refine BrS risk stratification; leaves open whether this improves clinical outcomes.
Background The utility of late potentials on signal-averaged electrocardiography (SAECG) for risk stratification in patients with Brugada syndrome (BrS) remains controversial. Late potentials on conventional SAECG with Frank leads may be insufficiently sensitive to detect site-specific late potentials in right precordial leads. Objective The purpose of this study was to evaluate the utility of site-specific late potentials using a novel unipolar Holter-SAECG system for risk stratification in patients with BrS. Methods Consecutive symptomatic (n = 20) and asymptomatic (n = 21) patients with BrS who underwent investigation using conventional SAECG and a novel unipolar Holter-SAECG system were enrolled. We evaluated clinical characteristics and outcomes and compared late potentials on the 2 SAECGs between both groups and patients with and without cardiac events (CEs) (sudden cardiac death or sustained ventricular tachyarrhythmias) during the follow-up period. Results During mean follow-up of 76 months, 10 patients (24%) had CEs. There were no significant differences in late potentials on conventional SAECG between symptomatic and asymptomatic patients. On the Holter-SAECG system, RMS40 in lead V 2 in the third intercostal space (3L-V 2 ) at the nighttime was significantly lower in the symptomatic group than in the asymptomatic group (5.5 ± 0.8 μV and 8.2 ± 0.8 μV, respectively; P = .027). Univariate analysis of predictive values for CE showed that hazard ratios of daytime and nighttime RMS40 in lead 3L-V 2 of <7.7 μV and <6.1 μV were 7.58 and 6.14, respectively. Conclusion Site-specific late potentials in lead 3L-V 2 measured using the novel Holter-SAECG system may be a useful marker for high-risk patients with BrS.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2022) conducted an observational in Brugada syndrome (n=41). Nighttime RMS40 < 6.1 μV in lead 3L-V2 via Holter-SAECG vs. Nighttime RMS40 ≥ 6.1 μV was evaluated on VT/VF recurrence (HR 6.14, 95% CI 1.51-41.1, p=0.01). Nighttime RMS40 < 6.1 μV in the third intercostal space lead V2 detected by a novel Holter-SAECG significantly predicted VT/VF recurrence in patients with Brugada syndrome (HR 6.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: